本帖最后由 老马 于 2012-1-13 21:20 编辑 0 H, L8 e1 A0 x; w+ k3 D
3 v Y1 `3 b( A' h8 a( l爱必妥和阿瓦斯丁的比较
3 v( r. k5 [' d$ \
9 u8 W! g6 Z/ v) }' |+ v
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
: r0 k# t1 `% K
: k0 _1 l% }0 F% m% I
& [8 w1 P. p, I6 u- ohttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
7 B7 ?0 V- d3 M; n==================================================. j b) }4 Z# z! z3 Y/ L9 U7 E
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) o V8 _8 u! ]# e: A' R
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.$ F/ E& Y8 I, v" ]( K- J' I
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* ?: I' b& H! }. W/ _
|